CLINICAL_TRIALS
trial_result
· 2012-02-13
Clinical Trial Update: Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes [Phase 1]
Summary
A Phase 1 study assessing safety, tolerability and pharmacodynamics of CYT013-IL1bQb in patients with Type 2 Diabetes.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Cytos Biotechnology AG | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED